ISSN: 1859 - 2872
Treatment and follow up of brain metastasis from papillary thyroid carcinoma: A case series in 108 Military Central Hospital
Main Article Content
Keywords
Papillary thyroid carcinoma, brain metastasis, MRI
Abstract
The brain is an unusual site for distant metastases of papillary thyroid carcinoma (PTC), with a frequency of 0.15%-1.3%. The metastases from PTC often dissiminate to lungs, bones, soft tissuses and brain... with poor prognosis. However, few of those brain metastatic patients have initial neurological symptoms suggestive of brain lesions. MRI, 131I-whole-body scan, SPECT/CT and 18F-FDG PET/CT) could detect brain metastasis. There are no standardized therapy strategies for metastatic brain lesions from PTC but mainly rely on brain metastatic cancer treatment guidelines and clinical experiences. We present a case series of brain metastasis patients from papillary thyroid carcinoma in Nuclear Medicine Department, 108 Military Central Hospital in recent 5 years and discusses treatment approaches in those rare patients.
Article Details
References
1. Drappatz J, Avila EK, and Wen PY (2018) Seizures in patients with primary and metastatic brain tumors. Uptodate. This topic last updated: Mar 08, 2023.
2. Gomes-Lima CJ, Wu D, Rao SN, Punukollu S, Hritani R, Zeymo A, Deeb H, Mete M, Aulisi EF, Van Nostrand D, Jonklaas J, Wartofsky L, Burman KD (2019) Brain metastases from differentiated thyroid carcinoma: Prevalence, current therapies, and outcomes. Journal of the Endocrine Society 3(2): 359-371.
3. Hardesty DA, Nakaji P (2016) The current and future treatment of brain metastases. Frontiers in surgery 3: 30.
4. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2017) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: What is new and what has changed?. Cancer 123(3): 372-381.
5. Linskey ME, Andrews DW, Asher AL, Burri SH, Kondziolka D, Robinson PD, Ammirati M, Cobbs CS, Gaspar LE, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Ryken TC, Kalkanis SN (2010) The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. Journal of neuro-oncology 96(1): 45-68.
6. Chiu AC, Delpassand ES, and Sherman SI (1997) Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 82(11): 3637-3642.
7. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37(4): 745-751.
8. Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Ben Hassel M, Kouri M, Valeinis E, van den Berge D, Collette S, Collette L, Mueller RP (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. J Clin Oncol 29(2): 134-141.
9. McConahey WM, Hay ID, Woolner LB, van Heerden JA, Taylor WF (1986) Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 61(12): 978-996.
10. Parker LN, Wu SY, Kim DD, Kollin J, Prasasvinichai S (1986) Recurrence of papillary thyroid carcinoma presenting as a focal neurologic deficit. Arch Intern Med 146(10): 1985-1987.
11. Soffietti R, Trevisan E and Rudà R (2012) Targeted therapy in brain metastasis. Curr Opin Oncol 24(6): 679-86.
12. Vecht CJ, Hovestadt A, Verbiest HB, van Vliet JJ, van Putten WL (1994) Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: A randomized study of doses of 4, 8, and 16mg per day. Neurology 44(4): 675-680.
2. Gomes-Lima CJ, Wu D, Rao SN, Punukollu S, Hritani R, Zeymo A, Deeb H, Mete M, Aulisi EF, Van Nostrand D, Jonklaas J, Wartofsky L, Burman KD (2019) Brain metastases from differentiated thyroid carcinoma: Prevalence, current therapies, and outcomes. Journal of the Endocrine Society 3(2): 359-371.
3. Hardesty DA, Nakaji P (2016) The current and future treatment of brain metastases. Frontiers in surgery 3: 30.
4. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2017) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: What is new and what has changed?. Cancer 123(3): 372-381.
5. Linskey ME, Andrews DW, Asher AL, Burri SH, Kondziolka D, Robinson PD, Ammirati M, Cobbs CS, Gaspar LE, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Ryken TC, Kalkanis SN (2010) The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. Journal of neuro-oncology 96(1): 45-68.
6. Chiu AC, Delpassand ES, and Sherman SI (1997) Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 82(11): 3637-3642.
7. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37(4): 745-751.
8. Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Ben Hassel M, Kouri M, Valeinis E, van den Berge D, Collette S, Collette L, Mueller RP (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. J Clin Oncol 29(2): 134-141.
9. McConahey WM, Hay ID, Woolner LB, van Heerden JA, Taylor WF (1986) Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 61(12): 978-996.
10. Parker LN, Wu SY, Kim DD, Kollin J, Prasasvinichai S (1986) Recurrence of papillary thyroid carcinoma presenting as a focal neurologic deficit. Arch Intern Med 146(10): 1985-1987.
11. Soffietti R, Trevisan E and Rudà R (2012) Targeted therapy in brain metastasis. Curr Opin Oncol 24(6): 679-86.
12. Vecht CJ, Hovestadt A, Verbiest HB, van Vliet JJ, van Putten WL (1994) Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: A randomized study of doses of 4, 8, and 16mg per day. Neurology 44(4): 675-680.
Article Sidebar
Published
Sep 29, 2023
Section
Articles
How to Cite
KhánhL. Q., SơnM. H., & HàL. N. (2023). Treatment and follow up of brain metastasis from papillary thyroid carcinoma: A case series in 108 Military Central Hospital . Tạp Chí Y Dược lâm sàng 108, 18(YHHN). https://doi.org/10.52389/ydls.v18iYHHN.1936